 |
49 Diseases |  |
8 Trials |
|
8 Trials |  |
104 News |  |
| «12 |
- | efavirenz / Generic mfg.
Trial completion: SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women (clinicaltrials.gov) - Oct 20, 2017
P1, N=26, Completed, Sponsor: St Stephens Aids Trust
Active, not recruiting --> Completed
- | lamivudine/zidovudine / Generic mfg.
Trial initiation date, Metastases: A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 25, 2017
P2, N=32, Not yet recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Initiation date: May 2017 --> Aug 2017
- efavirenz / Generic mfg.
Trial primary completion date: SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women (clinicaltrials.gov) - Jul 25, 2017
P1, N=25, Active, not recruiting, Sponsor: St Stephens Aids Trust
Initiation date: May 2017 --> Aug 2017 Trial primary completion date: Jun 2017 --> Oct 2017
- | Enrollment closed, Trial primary completion date: STATIS: Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 (clinicaltrials.gov) - Jul 12, 2017
P4, N=1050, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Trial primary completion date: Jun 2017 --> Oct 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Nov 2017
- efavirenz / Generic mfg.
Trial primary completion date: Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid (clinicaltrials.gov) - Jun 21, 2017
P1, N=35, Recruiting, Sponsor: St Stephens Aids Trust
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Nov 2017 Trial primary completion date: Jun 2017 --> Jan 2018
- efavirenz / Generic mfg.
Enrollment closed: SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women (clinicaltrials.gov) - Jun 12, 2017
P1, N=25, Active, not recruiting, Sponsor: St Stephens Aids Trust
Trial primary completion date: Jun 2017 --> Jan 2018 Recruiting --> Active, not recruiting
- Trial completion: A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV (clinicaltrials.gov) - May 23, 2017
P4, N=0, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- | lamivudine/zidovudine / Generic mfg.
New P2 trial, Metastases: A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - May 9, 2017
P2, N=32, Not yet recruiting, Sponsor: Massachusetts General Hospital
- nevirapine / Generic mfg., lamivudine/zidovudine / Generic mfg.
Enrollment closed, Trial primary completion date: Nevirapine Clearance After Short-term Highly Active Antiretroviral Therapy (HAART) for Prevention of Mother to Child Transmission of HIV (PMTCT) (clinicaltrials.gov) - Jan 19, 2017
P=N/A, N=30, Active, not recruiting, Sponsor: Thai Red Cross AIDS Research Centre
No longer recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2018 --> Apr 2019
- efavirenz / Generic mfg.
Enrollment open: Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid (clinicaltrials.gov) - Dec 28, 2016
P1, N=35, Recruiting, Sponsor: St Stephens Aids Trust
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2018 --> Apr 2019 Not yet recruiting --> Recruiting
- | efavirenz / Generic mfg.
New P1 trial: Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid (clinicaltrials.gov) - Jul 14, 2016
P1, N=35, Not yet recruiting, Sponsor: St Stephens Aids Trust
- efavirenz / Generic mfg.
Trial primary completion date: SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women (clinicaltrials.gov) - May 26, 2016
P1, N=25, Recruiting, Sponsor: St Stephens Aids Trust
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2016 --> Feb 2017
- | lamivudine/zidovudine / Generic mfg.
Trial completion: Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma (clinicaltrials.gov) - Feb 1, 2016
P2, N=19, Completed, Sponsor: AIDS Malignancy Consortium
Trial primary completion date: Feb 2016 --> Feb 2017 Active, not recruiting --> Completed
- efavirenz / Generic mfg.
Enrollment open: SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women (clinicaltrials.gov) - Oct 22, 2015
P1, N=25, Recruiting, Sponsor: St Stephens Aids Trust
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | NN1213 / Novo Nordisk
Trial completion, Discordant: Preventing Sexual Transmission of HIV With Anti-HIV Drugs (clinicaltrials.gov) - Aug 13, 2015
P3, N=3500, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- efavirenz / Generic mfg.
New P1 trial: SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women (clinicaltrials.gov) - Jul 16, 2015
P1, N=25, Not yet recruiting, Sponsor: St Stephens Aids Trust
- |||| lopinavir/ritonavir / Generic mfg.
Trial completion: Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa (clinicaltrials.gov) - Jun 24, 2015
P4, N=280, Completed, Sponsor: University of Zambia
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial primary completion date, IO biomarker: Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV (clinicaltrials.gov) - Mar 9, 2015
P=N/A, N=398, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Aug 2006 --> Oct 2008
- Rescriptor (delavirdine mesylate) / ViiV Healthcare, Invirase (saquinavir) / Roche, Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment change, Combination therapy: A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients (clinicaltrials.gov) - Mar 9, 2015
P2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Aug 2006 --> Oct 2008 N=400 --> 0
- ||| lamivudine/zidovudine / Generic mfg.
New P1 trial: Study of Pharmacokinetic Interaction Between Combivir (clinicaltrials.gov) - Oct 10, 2014
P1, N=51, Completed, Sponsor: Boehringer Ingelheim
- Enrollment open, Trial initiation date, Trial primary completion date: STATIS: Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 (clinicaltrials.gov) - Oct 10, 2014
P4, N=1050, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
N=400 --> 0 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Sep 2014 | Trial primary completion date: Dec 2016 --> Apr 2017
- ||||||| efavirenz / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lamivudine/zidovudine / Generic mfg.
Trial completion, Combination therapy: Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects (clinicaltrials.gov) - Feb 22, 2014
P3, N=517, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Sep 2014 | Trial primary completion date: Dec 2016 --> Apr 2017 Active, not recruiting --> Completed
- | Invirase (saquinavir) / Roche
Trial completion, Combination therapy: Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects (clinicaltrials.gov) - Feb 22, 2014
P2, N=30, Completed, Sponsor: Abbott
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Viracept (nelfinavir) / ViiV Healthcare, Roche, NN1213 / Novo Nordisk
Trial completion: Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy (clinicaltrials.gov) - Feb 19, 2014
P3, N=440, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- Trial completion, Combination therapy: A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- | New P4 trial: STATIS: Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 (clinicaltrials.gov) - Feb 5, 2014
P4, N=1050, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- |||| Selzentry (maraviroc) / ViiV Healthcare
Trial completion: Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia (clinicaltrials.gov) - Jul 29, 2013
P4, N=98, Completed, Sponsor: ViiV Healthcare
No longer recruiting --> Completed Recruiting --> Completed
- | nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P4 trial, IO biomarker: Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting (clinicaltrials.gov) - Jan 17, 2013
P4, N=425, Completed, Sponsor: Centre Hospitalier Universitaire Saint Pierre
- lamivudine/zidovudine / Generic mfg.
Trial completion: Zidovudine and Lamivudine Given Once Versus Twice Daily (clinicaltrials.gov) - Oct 24, 2012
P1, N=20, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial completion, IO biomarker: Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=398, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- nevirapine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lamivudine/zidovudine / Generic mfg.
Enrollment change: Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT) (clinicaltrials.gov) - Aug 23, 2012
P=N/A, N=566, Completed, Sponsor: Rigshospitalet, Denmark
Active, not recruiting --> Completed N=450 --> 566
- nevirapine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lamivudine/zidovudine / Generic mfg.
Trial completion: Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT) (clinicaltrials.gov) - Aug 23, 2012
P=N/A, N=566, Completed, Sponsor: Rigshospitalet, Denmark
N=450 --> 566 Recruiting --> Completed
- | Selzentry (maraviroc) / ViiV Healthcare
New P1 trial: A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir (clinicaltrials.gov) - May 10, 2012
P1, N=42, Completed, Sponsor: GlaxoSmithKline
- lopinavir/ritonavir / Generic mfg., lamivudine/zidovudine / Generic mfg.
Trial completion: Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir (clinicaltrials.gov) - Apr 10, 2012
P4, N=50, Completed, Sponsor: Kirby Institute
Recruiting --> Completed Active, not recruiting --> Completed
- |||| Edurant (rilpivirine) / J&J
Trial completion: A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines (clinicaltrials.gov) - Apr 5, 2012
P2b, N=372, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial completion: A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants (clinicaltrials.gov) - Feb 15, 2012
P1, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed